Antimicrobials
Voriconazole

Voriconazole

Restricted

Low
N/A
IV$$$$$$ PO$$$$$

Spectrum of Activity

General Information

  • Candida infections
  • Antifungal prophylaxis in immunocompromised
  • Therapeutic drug monitoring may be helpful to ensure adequate concentrations and exclude toxicity (discuss with ID)
  • Monitor QTc interval in patients at elevated risk
  • Monitor hepatic profile
  • QTc prolongation
  • Hepatic enzyme abnormalities
  • Rash: Up to 20%
  • GI upset
  • Visual disturbances commonly associated with treatment, usually reversible with duration of use < 28 days
  • Many via CYP450 - suggest review interactions with pharmacist
  • Risk when combining with other QTc prolonging agents

Prisma Health Inpatient Formulary
Suspension: 40 mg/mL

Prisma Health Inpatient Formulary
Tablet: 50 mg, 200 mg

Do not infuse concomitantly into same line or cannula with other drug infusions, including TPN.

Antimicrobial class: Triazole antifungal, second generation

Average serum half-life: Variable and dose dependent

Route of Elimination: Urine (<2% as unchanged drug)